Teams

  • Annoviant, Inc.

    Annoviant is advancing patient outcomes in heart disease by delivering innovative, regenerative cardiovascular devices built on its proprietary TxGuard™ soft-tissue technology.

    The platform enables durable, off-the-shelf…

  • Avast Therapeutics

    Avast Therapeutics is developing first-in-class, non-invasive peptide therapeutics that safely cross the blood-brain barrier to restore mitochondrial function and protect neurons.

    This…

  • Bluegrass Pharmaceuticals Inc.

    Bluegrass Pharmaceuticals develops advanced Lipid Nanoparticles (LNPs) to enhance vaccine efficacy and enable targeted therapeutic delivery.

  • Kifa Therapeutics, Inc.

    Kifa Therapeutics advances highly selective CNS-kinase inhibitors, starting with a G2019S-LRRK2 therapy for Parkinson’s disease.

    Our strategy pairs genetics-based patient selection with…

  • Nemea Therapeutics

    Nemea Therapeutics is a preclinical-stage company developing oral small molecule inhibitors targeting mitochondrial RNA polymerase (POLRMT) for the treatment of mitochondria-dependent solid tumors.